PIC and Its Role in Progression of Pathological Myopia

June 15, 2021 updated by: shymaa kamel Ibrahim Hady, Assiut University

Punctate Inner Choroidopathy (PIC) and Its Role in Progression of Pathological Myopia

Aim of the work PIC in pathological myopia has not been well documented due to difficult in diagnosis we conducted this retrospective study to characterize the clinical features of PIC in high myopic eye.

  • To show the diagnostic criteria of PIC lesions in high myopic patients.
  • Find out the prevalence of PIC related 'patchy atrophy'
  • To determine risk factor for developed PIC in a series of highly myopic patients.
  • Role of PIC in progression of high myopia.
  • Calculate the progression rate of PIC related lesion, by the size change during follow-up.
  • Search about complication of PIC in myopia. Patient and Methods This retrospective observational case series study included patients with high myopia who had been examined and followed-up in the High Myopia Clinic of the Tokyo Medical and Dental University. Approval from Ethics Committee of Tokyo Medical and Dental University was obtained, adhering to the tenets of Declaration of Helsinki. Signed informed consent documentation was obtained from all participants.

All study participants underwent a detailed ophthalmologic examination at baseline and at each follow-up visit. The examinations included measurements of best-corrected visual acuity (BCVA) using a Landolt C chart, refraction, slit lamp biomicroscopy, biometry for determination of axial length, (IOL Master; Carl Zeiss Meditec Co, Jena, Germany), fundus examination in medical mydriasis, fluorescein angiography, was performed with and colour fundus photography , and assessment of fundus autofluorescence (TRC-50DX; Topcon, Tokyo, Japan) a or the Heidelberg Spectralis HRA system. Swept source Optical coherence tomography (OCT) used in assessment of the RPE and photoreceptors using a (DRI-OCT;Topcon, Tokyo, Japan). As scanning protocols, 9 mm or 6 mm radial with 12 equal meridian scans were performed. The swept-source OCT device has an A-scan repetition rate of 100 000 Hz, and its light source operates in the wavelength range of 1 μm.

Study Overview

Status

Unknown

Detailed Description

Myopia The frequency of myopia and high myopia are growing on a worldwide for causes that not cleared. Myopia is vision challenges due to rises the risk of pathologic ophthalmic changes such as cataract, glaucoma, retinal detachment, and myopic macular degeneration, all of which can cause permanent vision loss.

High myopia was defined as an error of refractive above 8.0 diopters (D) or an axial length of 26.5 mm or more. Younger persons than 5 years, high myopia was defined by a refractive error of below- 4.0 D, and in children between 5 to 8 years, high myopia was defined by error of refraction below -6.0 D.

The term of pathologic myopia," "high myopia," and "axial myopia" have been used as a same in the literature. Pathologic myopia was defined as chorioretinal atrophy (by META-PM study group classification) with/or the existence of posterior staphylomas. Pathologic myopia is an significant origin of vision loss global, affecting up to 3% of the people. The effect of myopic maculopathy on impairment of vision is critical because the maculopathy is often affect both eye , permanent, and usually affects individuals in productive years.

Punctate inner choroidopathy Definition Punctate inner choroidopathy (PIC), classically bilateral and is considers one of "white dot syndromes" which usually presents with distinct ,multiple white-yellow lesions at posterior pole in the level of inner choroid and outer retina with a preference for young myopic female , without sign of old or recent anterior chamber or vitreous inflammation , with an increase the incidence of macular neovascularization (MNV).

ETIOLOGY The underlying pathophysiology are not completely understood. Multiple evanescent white dot syndrome( MEWDS)-like findings have been presented after traumatic subretinal bleeding, choroidal rupture, and penetrating injury or with angioid streaks, ensuring antigen exposure is likely causative factor. The present of acute retinopathy in Pseudoxanthoma elasticum (PXE) is marked along angioid streaks (breaks in the Bruch membrane), in which contact of retinal, RPE, and the Bruch membrane antigens to the immune system which stimulate an autoimmune system.

. Most inflammatory conditions in myopia are including the choriocapillaris. It can be suggested that weakness of the choriocapillaris due to anatomic changes in addition to unknown immunogenetic factors potentiate myopic eyes to primary inflammatory choriocapillaropathies.

CLINICAL FINDINGS Symptom Vision was usually slightly affected until the lesions were subfoveal or choroidal neovascular membranes developed.(8) According to the study by Gerstenblith and colleagues, initial symptoms in PIC are mostly scotoma (91%), blurred vision (86%), photopsia (73%), floaters (69%), photophobia (69%), and metamorphopsia (65%). Loss of peripheral vision was reported in 26% of patients. The consequence variable from return to the normal to bilateral profound loss of vision .

Sign Tools used in detecting and following PIC have involved fluorescein angiography, indocyanine green angiography, and OCT ,fundus autofluorescence (FAF) imaging and OCT angiography.

Fundoscopic features Small (100-300 microns), yellow-gray lesions (12-25 in number) which usually limited to the posterior pole and scattered in a haphazard (or rarely, linear) form.

The development of chorioretinal scars is frequency to occur as consequence at the sites of inflammation. Then, these scars become increasingly to well-defined ("punched out") and may come to be pigmented. These scars may progressively enlarge in size, leading to deterioration of symptoms over time.

OCT finding:

Stage I: minor irregularities change in the outer nuclear layer. Stage II: focal elevation of the retinal pigment epithelium/Bruch's membrane (RPE/BrM) complex with EZ and interdigitation zone disruption. Stage III: The lesion of moderate reflectivity breakdowns through the RPE and then grow to the dome of OPL through the photoreceptor layer. The RPE remain and BM at the break gradually disappear, exposing the choroidal part of the lesion. Stage IV: The lesion descends from the peak toward the choroidal part, subsequently a herniation of the OPL and inner retina (with a V-shaped change) through the defect in the RPE and BM. Stage V: The photoreceptor layer around the lesion is progressively missing with the drooping of the OPL and inner retina. This lead to V-shaped inward of the outer plexiform layer and inner retina into the choroid this is called "focal choroidal excavation .At the same time, RPE proliferation occurs (with posterior shadowing) to repair the RPE break so, the OPL framework reappear .

BM (Bruch's membrane); OPL (outer plexiform layer;) RPE ( retinal pigment epithelium), SD-OCT( spectral-domain optical coherence tomography).

fluorescein angiography (FA)& Indocyanine green angiography (ICG) FA in PIC patients show early hypofluorescence with late staining of inflammatory lesions, early hyperfluorescence can also happen, particularly if CNV is found. ICG shows midphase hypocyanescence at the posterior pole that may go beyond the lesions visible on FA and fundus.

Fundus autofluorescence (FAF) Active PIC lesions show hypoautofluorescent spots with a hyperautofluorescent border that disappear as the lesions regress. Atrophic PIC lesions display to be hypoautofluorescent.

Complication Serious visual loss occurs in about to 40% of patients mainly due to development of choroidal neovascularization (CNV). The Important associations of myopic choroidal neovascularization (MCNV) in highly myopic eyes with increasing levels of vascular endothelial growth factor or inflammatory cytokines and maculopathy lesions firmly indicate an association of inflammation in the cause of MCNVs.

Management The PIC management is tricky for multiple reasons. The varying in seriousness of disease between patients make that ideal l treatment range from observation to immunosuppression or intravitreal anti-VEGF therapy. The judgment whether a patient is benefit from maintenance therapy is hard due to the need to sense of balance between the varying outcome of patients with PIC and the hazards of immunosuppression. Large number of patients with PIC have prolonged times without disease activity and may go into long-standing remission, although in others these stable stages may be interrupted by unpredictable, sight-threatening episodes. Also, the evidence base to recommend any treatment approach is inadequate There is large difference between patients. So, mediation is necessary to treat new or active inflammatory "PIC" lesions especially when threatening the fovea, and to handle secondary CNV. Also, addition, the situation of the other eye requires attention.

The treatment options include local and systemic corticosteroids, systemic immunomodulatory drugs, intravitreal VEGF inhibitors (anti-VEGF), photodynamic therapy (PDT), argon laser, and submacular surgery.

Study Type

Observational

Enrollment (Actual)

39

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tokyo, Japan
        • Tokyo Medical and Dental University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

we will enroll all high myopic patient with punctate inner choriodopathy lesion who have follow up period not less than 2 years.

Description

Inclusion Criteria:

  • Highly myopic patients.
  • Men and women aged over 18 years
  • Fundus changes typical of pathological myopia
  • Minimum follow up period of 2 years

Exclusion Criteria:

  • Another choroidal lesion other than MFC.
  • Media opacity interfere with quality of image taking.
  • Alternative diagnosis (especially other white dot syndromes or when it was unclear whether the lesions were due to pathologic myopia)
  • If they had an underlying systemic condition that could mimic PIC (e.g., sarcoidosis, TB,)
  • If they had history of travel to Histoplasma-endemic regions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic criteria of PIC in high or pathological myopic.
Time Frame: about 7 mounth
Pick up the characteristic fundus feature and OCT finding of inflammatory lesion in pathological myopia cases
about 7 mounth
Calculate the progression rate of PIC related lesion.
Time Frame: about 7 mounth
By measure the size of patchy atrophy changes during follow-up.
about 7 mounth
Development of complication as inflammatory choroidal neovascularization.
Time Frame: about 7 mounth
Pick up the occurrence of inflammatory CNV during follow up period on fundus picture OCT images ,FA , and OCTA
about 7 mounth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of PIC in pathological myopia.
Time Frame: about 7 mounth
The number of PIC patients in pathological myopia during this retrospective study of long follow up period
about 7 mounth
Final visual acuity.
Time Frame: about 7 mounth
show the visual acuity of each patients at initial and last visits
about 7 mounth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shymaa Kl Hady, As Lec, Department of Ophthalmology , Assiut University
  • Study Chair: Kyoko Oh Matsui, Prof, ,Department of Ophthalmology Tokyo Medical and Dental University
  • Study Chair: Omar Mo Ali, Prof, Department of Ophthalmology , Assiut University
  • Study Director: Ehab Is Wasfi, As prof, Department of Ophthalmology , Assiut University
  • Study Director: Mahmoud Fa Rateb, As prof, Department of Ophthalmology , Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2020

Primary Completion (Anticipated)

October 15, 2021

Study Completion (Anticipated)

November 15, 2021

Study Registration Dates

First Submitted

September 18, 2020

First Submitted That Met QC Criteria

September 18, 2020

First Posted (Actual)

September 24, 2020

Study Record Updates

Last Update Posted (Actual)

June 18, 2021

Last Update Submitted That Met QC Criteria

June 15, 2021

Last Verified

September 1, 2020

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Punctate Inner Choroidopathy

3
Subscribe